{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T20:13:12Z","timestamp":1792699992058,"version":"4.5.0"},"reference-count":52,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2019,3]]},"DOI":"10.1016\/j.jaad.2018.10.039","type":"journal-article","created":{"date-parts":[[2018,10,26]],"date-time":"2018-10-26T12:01:35Z","timestamp":1540555295000},"page":"608-616","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Markers of systemic involvement and death in hospitalized cancer patients with severe cutaneous adverse reactions"],"prefix":"10.1016","volume":"80","author":[{"given":"Shoko","family":"Mori","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alanna","family":"Hickey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen W.","family":"Dusza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario E.","family":"Lacouture","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alina","family":"Markova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"19","key":"10.1016\/j.jaad.2018.10.039_bib1","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1056\/NEJM199411103311906","article-title":"Severe adverse cutaneous reactions to drugs","volume":"331","author":"Roujeau","year":"1994","journal-title":"New Engl J Med"},{"issue":"5","key":"10.1016\/j.jaad.2018.10.039_bib2","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1111\/j.1365-2133.2007.08156.x","article-title":"Risk factors for acute generalized exanthematous pustulosis (AGEP)-results of a multinational case-control study (EuroSCAR)","volume":"157","author":"Sidoroff","year":"2007","journal-title":"Br J Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2018.10.039_bib3","doi-asserted-by":"crossref","first-page":"173.e1","DOI":"10.1016\/j.jaad.2013.05.003","article-title":"Toxic epidermal necrolysis: Part I. Introduction, history, classification, clinical features, systemic manifestations, etiology, and immunopathogenesis","volume":"69","author":"Schwartz","year":"2013","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"10.1016\/j.jaad.2018.10.039_bib4","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1111\/j.1365-2133.2003.05584.x","article-title":"A 6-month prospective survey of cutaneous drug reactions in a hospital setting","volume":"149","author":"Fiszenson-Albala","year":"2003","journal-title":"Br J Dermatol"},{"issue":"5","key":"10.1016\/j.jaad.2018.10.039_bib5","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1111\/bjd.12501","article-title":"Drug reaction with eosinophilia and systemic symptoms (DRESS): an original multisystem adverse drug reaction. Results from the prospective RegiSCAR study","volume":"169","author":"Kardaun","year":"2013","journal-title":"Br J Dermatol"},{"issue":"10106","key":"10.1016\/j.jaad.2018.10.039_bib6","doi-asserted-by":"crossref","first-page":"1996","DOI":"10.1016\/S0140-6736(16)30378-6","article-title":"Severe cutaneous adverse reactions to drugs","volume":"390","author":"Duong","year":"2017","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.jaad.2018.10.039_bib7","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1016\/j.jid.2017.01.031","article-title":"The epidemiology of Stevens-Johnson syndrome and toxic epidermal necrolysis in the UK","volume":"137","author":"Frey","year":"2017","journal-title":"J Invest Dermatol"},{"issue":"9","key":"10.1016\/j.jaad.2018.10.039_bib8","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.1016\/j.jid.2017.05.010","article-title":"Incidence and triggers of Stevens-Johnson syndrome and toxic epidermal necrolysis in a large cancer patient cohort","volume":"137","author":"Gillis","year":"2017","journal-title":"J Invest Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2018.10.039_bib9","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/sj.jid.5701033","article-title":"Stevens-Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR-study","volume":"128","author":"Mockenhaupt","year":"2008","journal-title":"J Invest Dermatol"},{"issue":"5","key":"10.1016\/j.jaad.2018.10.039_bib10","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1111\/bjd.14052","article-title":"Stevens-Johnson syndrome and toxic epidermal necrolysis in patients with malignancies","volume":"173","author":"Wu","year":"2015","journal-title":"Br J Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2018.10.039_bib11","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1001\/archderm.145.1.67","article-title":"Twelve-year analysis of severe cases of drug reaction with eosinophilia and systemic symptoms: a cause of unpredictable multiorgan failure","volume":"145","author":"Eshki","year":"2009","journal-title":"Arch Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2018.10.039_bib12","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1159\/000354918","article-title":"Clinical features and prognostic factors in severe cutaneous drug reactions","volume":"162","author":"Yang","year":"2013","journal-title":"Int Arch Allergy Immunol"},{"issue":"7","key":"10.1016\/j.jaad.2018.10.039_bib13","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1080\/17425255.2017.1297422","article-title":"Prediction and management of drug reaction with eosinophilia and systemic symptoms (DRESS)","volume":"13","author":"Shiohara","year":"2017","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"4","key":"10.1016\/j.jaad.2018.10.039_bib14","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.jaad.2004.02.019","article-title":"Tissue eosinophils and the perils of using skin biopsy specimens to distinguish between drug hypersensitivity and cutaneous graft-versus-host disease","volume":"51","author":"Marra","year":"2004","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2018.10.039_bib15","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1097\/DAD.0b013e3181a85293","article-title":"Quantitative analysis of eosinophils in acute graft-versus-host disease compared with drug hypersensitivity reactions","volume":"32","author":"Weaver","year":"2010","journal-title":"Am J Dermatopathology"},{"issue":"4","key":"10.1016\/j.jaad.2018.10.039_bib16","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1182\/blood-2009-01-197178","article-title":"Blockade of interleukin-6 signaling augments regulatory T-cell reconstitution and attenuates the severity of graft-versus-host disease","volume":"114","author":"Chen","year":"2009","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.jaad.2018.10.039_bib17","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1097\/PPO.0000000000000035","article-title":"Managing cytokine release syndrome associated with novel T cell-engaging therapies","volume":"20","author":"Maude","year":"2014","journal-title":"Cancer J"},{"issue":"6","key":"10.1016\/j.jaad.2018.10.039_bib18","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1111\/bjd.13146","article-title":"A case of tumour necrosis factor-alpha inhibitor- and rituximab-induced plantar pustular psoriasis that completely resolved with tocilizumab","volume":"171","author":"Jayasekera","year":"2014","journal-title":"Br J Dermatol"},{"issue":"8","key":"10.1016\/j.jaad.2018.10.039_bib19","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1634\/theoncologist.2018-0028","article-title":"FDA approval summary: tocilizumab for treatment of chimeric antigen receptor T cell-induced severe or life-threatening cytokine release syndrome","volume":"23","author":"Le","year":"2018","journal-title":"Oncologist"},{"issue":"11","key":"10.1016\/j.jaad.2018.10.039_bib20","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.1002\/pbc.25595","article-title":"Fulminant skin GvHD with a cytokine pattern resemblant of cytokine release syndrome successfully treated with multimodal immunosuppression including tocilizumab","volume":"62","author":"Hellwig","year":"2015","journal-title":"Pediatr Blood Cancer"},{"issue":"3","key":"10.1016\/j.jaad.2018.10.039_bib21","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1111\/j.1365-2133.2006.07704.x","article-title":"Variability in the clinical pattern of cutaneous side-effects of drugs with systemic symptoms: does a DRESS syndrome really exist?","volume":"156","author":"Kardaun","year":"2007","journal-title":"Br J Dermatol"},{"issue":"25","key":"10.1016\/j.jaad.2018.10.039_bib22","doi-asserted-by":"crossref","first-page":"14791","DOI":"10.1016\/S0021-9258(18)77182-2","article-title":"Elafin: an elastase-specific inhibitor of human skin. Purification, characterization, and complete amino acid sequence","volume":"265","author":"Wiedow","year":"1990","journal-title":"J Biol Chem"},{"issue":"13","key":"10.1016\/j.jaad.2018.10.039_bib23","doi-asserted-by":"crossref","first-page":"13ra12","DOI":"10.1126\/scitranslmed.3000406","article-title":"Elafin is a biomarker of graft-versus-host disease of the skin","volume":"2","author":"Paczesny","year":"2010","journal-title":"Sci Translational Med"},{"issue":"4","key":"10.1016\/j.jaad.2018.10.039_bib24","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1046\/j.1365-2133.2000.03766.x","article-title":"Elafin is induced in epidermis in skin disorders with dermal neutrophilic infiltration: interleukin-1 beta and tumour necrosis factor-alpha stimulate its secretion in\u00a0vitro","volume":"143","author":"Tanaka","year":"2000","journal-title":"Br J Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2018.10.039_bib25","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1111\/1523-1747.ep12471990","article-title":"Immunohistochemical localization of SKALP\/elafin in psoriatic epidermis","volume":"100","author":"Schalkwijk","year":"1993","journal-title":"J Invest Dermatol"},{"issue":"6","key":"10.1016\/j.jaad.2018.10.039_bib26","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1038\/sj.jid.5700647","article-title":"Accumulation of elafin in actinic elastosis of sun-damaged skin: elafin binds to elastin and prevents elastolytic degradation","volume":"127","author":"Muto","year":"2007","journal-title":"J Invest Dermatol"},{"issue":"9","key":"10.1016\/j.jaad.2018.10.039_bib27","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1111\/jdv.13650","article-title":"Deposition of elafin in the involved vascular wall of neutrophil-mediated cutaneous vasculitis","volume":"30","author":"Muto","year":"2016","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"8","key":"10.1016\/j.jaad.2018.10.039_bib28","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1007\/BF02505235","article-title":"Expression of SKALP\/elafin during wound healing in human skin","volume":"288","author":"van Bergen","year":"1996","journal-title":"Arch Dermatol Res"},{"issue":"6","key":"10.1016\/j.jaad.2018.10.039_bib29","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1165\/ajrcmb.11.6.7946401","article-title":"Regulation of secretory leukocyte proteinase inhibitor (SLPI) and elastase-specific inhibitor (ESI\/elafin) in human airway epithelial cells by cytokines and neutrophilic enzymes","volume":"11","author":"Sallenave","year":"1994","journal-title":"Am J Respir Cell Mol Biol"},{"issue":"4","key":"10.1016\/j.jaad.2018.10.039_bib30","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1007\/s004030050475","article-title":"TNF-alpha and serum induce SKALP\/elafin gene expression in human keratinocytes by a p38 MAP kinase-dependent pathway","volume":"292","author":"Pfundt","year":"2000","journal-title":"Arch Dermatol Res"},{"issue":"4","key":"10.1016\/j.jaad.2018.10.039_bib31","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1038\/jid.2014.489","article-title":"Epidermal elafin expression is an indicator of poor prognosis in cutaneous graft-versus-host disease","volume":"135","author":"Bruggen","year":"2015","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaad.2018.10.039_bib32","first-page":"1","article-title":"Toxic epidermal necrolysis versus cutaneous graft-versus-host disease in a hematopoietic stem cell transplant recipient: the role of elafin","author":"Chen","year":"2018","journal-title":"Leuk Lymphoma"},{"issue":"6","key":"10.1016\/j.jaad.2018.10.039_bib33","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.1007\/s11033-009-9865-z","article-title":"Recombinant human elafin protects airway epithelium integrity during inflammation","volume":"37","author":"Li","year":"2010","journal-title":"Mol Biol Rep"},{"issue":"1","key":"10.1016\/j.jaad.2018.10.039_bib34","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/mt.2014.162","article-title":"A functional variant of elafin with improved anti-inflammatory activity for pulmonary inflammation","volume":"23","author":"Small","year":"2015","journal-title":"Mol Ther"},{"issue":"5","key":"10.1016\/j.jaad.2018.10.039_bib35","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1007\/s12185-011-0803-1","article-title":"Implications of TNF-alpha in the pathogenesis and management of GVHD","volume":"93","author":"Levine","year":"2011","journal-title":"Int J Hematol"},{"issue":"1","key":"10.1016\/j.jaad.2018.10.039_bib36","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1067\/mjd.2002.120473","article-title":"Increased interleukin 10, tumor necrosis factor alpha, and interleukin 6 levels in blister fluid of toxic epidermal necrolysis","volume":"47","author":"Correia","year":"2002","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2018.10.039_bib37","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1080\/09546630802683843","article-title":"The molecular mechanism of etanercept, an anti-tumour necrosis factor-alpha receptor-fusion protein, in the treatment of acute generalized exanthematous pustulosis","volume":"20","author":"Gencoglan","year":"2009","journal-title":"J Dermatol Treat"},{"issue":"2","key":"10.1016\/j.jaad.2018.10.039_bib38","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.jaad.2014.04.044","article-title":"Etanercept therapy for toxic epidermal necrolysis","volume":"71","author":"Paradisi","year":"2014","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2018.10.039_bib39","first-page":"601412","article-title":"Acute generalized exanthematous pustulosis induced by etanercept: another dermatologic adverse effect","volume":"2013","author":"Kavala","year":"2013","journal-title":"Case Rep Dermatol Med"},{"issue":"4","key":"10.1016\/j.jaad.2018.10.039_bib40","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1046\/j.1365-2133.2002.46833.x","article-title":"Antitumour necrosis factor-alpha antibodies (infliximab) in the treatment of a patient with toxic epidermal necrolysis","volume":"146","author":"Fischer","year":"2002","journal-title":"Br J Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2018.10.039_bib41","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.jdcr.2017.05.006","article-title":"Drug reaction with eosinophilia and systemic symptoms (DRESS) successfully treated with tumor necrosis factor-alpha inhibitor","volume":"3","author":"Leman","year":"2017","journal-title":"JAAD Case Rep"},{"issue":"6","key":"10.1016\/j.jaad.2018.10.039_bib42","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1016\/j.cgh.2015.12.028","article-title":"Clinical, endoscopic, and histologic characteristics of ipilimumab-associated colitis","volume":"14","author":"Verschuren","year":"2016","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"7090","key":"10.1016\/j.jaad.2018.10.039_bib43","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1038\/nature04753","article-title":"Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells","volume":"441","author":"Bettelli","year":"2006","journal-title":"Nature"},{"key":"10.1016\/j.jaad.2018.10.039_bib44","first-page":"1","article-title":"IL-6 signal transduction and its physiological roles: the signal orchestration model","volume":"149","author":"Kamimura","year":"2003","journal-title":"Rev Physiol Biochem Pharmacol"},{"issue":"4","key":"10.1016\/j.jaad.2018.10.039_bib45","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1097\/ACI.0000000000000180","article-title":"Monitoring the acute response in severe hypersensitivity reactions to drugs","volume":"15","author":"Shiohara","year":"2015","journal-title":"Curr Opin Allergy Clin Immunol"},{"issue":"12","key":"10.1016\/j.jaad.2018.10.039_bib46","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.26642","article-title":"Severe cytokine release syndrome in a patient receiving PD-1-directed therapy","volume":"64","author":"Rotz","year":"2017","journal-title":"Pediatr Blood Cancer"},{"issue":"1-3","key":"10.1016\/j.jaad.2018.10.039_bib47","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.ejphar.2010.02.026","article-title":"Anti-IL-6 receptor antibody suppressed T cell activation by inhibiting IL-2 production and inducing regulatory T cells","volume":"634","author":"Yoshida","year":"2010","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.jaad.2018.10.039_bib48","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1146\/annurev-immunol-031210-101312","article-title":"Regulation and functions of the IL-10 family of cytokines in inflammation and disease","volume":"29","author":"Ouyang","year":"2011","journal-title":"Annu Rev Immunol"},{"issue":"2","key":"10.1016\/j.jaad.2018.10.039_bib49","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.anai.2014.05.006","article-title":"Chemokine expression in diverse nonimmediate drug hypersensitivity reactions: focus on thymus activation-regulated chemokine, cutaneous T-cell-attracting chemokine, and interleukin-10","volume":"113","author":"Wang","year":"2014","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"5","key":"10.1016\/j.jaad.2018.10.039_bib50","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1111\/j.0022-202X.2004.23439.x","article-title":"Evaluation of the potential role of cytokines in toxic epidermal necrolysis","volume":"123","author":"Nassif","year":"2004","journal-title":"J Invest Dermatol"},{"issue":"6","key":"10.1016\/j.jaad.2018.10.039_bib51","doi-asserted-by":"crossref","first-page":"dju124","DOI":"10.1093\/jnci\/dju124","article-title":"Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis","volume":"106","author":"Templeton","year":"2014","journal-title":"J Natl Cancer Inst"},{"issue":"6","key":"10.1016\/j.jaad.2018.10.039_bib52","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1016\/j.jaad.2017.12.031","article-title":"Inflammatory dermatoses, infections, and drug eruptions are the most common skin conditions in hospitalized cancer patients","volume":"78","author":"Phillips","year":"2018","journal-title":"J Am Acad Dermatol"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962218328093?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962218328093?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T22:47:56Z","timestamp":1759272476000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962218328093"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3]]},"references-count":52,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,3]]}},"alternative-id":["S0190962218328093"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2018.10.039","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2019,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Markers of systemic involvement and death in hospitalized cancer patients with severe cutaneous adverse reactions","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2018.10.039","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 by the American Academy of Dermatology, Inc.","name":"copyright","label":"Copyright"}]}}